Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB078 in C9ORF72-Associated ALS
NCT03626012Phase 1Completed
- Sponsor
- Biogen
- Start
- Sep 2018
- Primary completion
- Nov 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of tadnersen in amyotrophic lateral sclerosis (ALS) (7 arms), sponsored by Biogen. Primary endpoint: Number of Participants with Adverse Events at Day 323. Started Sep 2018; status: completed.
02
Drugs
tadnersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03626012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626012.